Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

PF-337210, a new, selective, orally bioavailable VEGFR-2 inhibitor

April 20, 2007

Development of new water-soluble topoisomerase I inhibitor reported by Chugai

April 20, 2007

BZL-101 begins phase I/II trial in advanced breast cancer

April 20, 2007

New PMEG prodrug with improved therapeutic index designed by Gilead

April 20, 2007

Biliary fibrosis aggravated by the antiangiogenic alpha(v)beta(3) antagonist cilengitide in rats

April 19, 2007

Alnylam to advance ALN-VSP01 for liver cancer

April 19, 2007

Inecalcitol shows high level of tolerance in phase I trial

April 19, 2007

Phase I results in cancer patients reported for CDK inhibitor P-276-00

April 19, 2007

First-in-class non-ATP-selective Src inhibitor designed by Kinex

April 19, 2007

Novel Met inhibitor from Pfizer with potential in osteosarcoma

April 19, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....